Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Journal of Managed Care Pharmacy : JMCP|December 4, 2009
Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney diseaseJeffrey Horowitz, Anil Agarwal, Fannie Huang, et al.
Advances in Therapy|March 14, 2012
Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisMachaon M K Bonafede, Shravanthi R Gandra, Crystal Watson, et al.
Journal of Medical Economics|September 14, 2017
Differences in utility elicitation methods in cardiovascular disease: a systematic reviewMarissa Blieden Betts, Shravanthi R Gandra, Lung-I Cheng, et al.
Current Medical Research and Opinion|March 16, 2013
Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationMaxine D Fisher, Crystal Watson, Kathleen M Fox, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 23, 2008
Further validation of an individualized migraine treatment satisfaction measureMona L Martin, Donald L Patrick, Donald M Bushnell, et al.
Journal of Oncology|July 10, 2009
Estimation of Cachexia among Cancer Patients Based on Four DefinitionsKathleen M Fox, John M Brooks, Shravanthi R Gandra, et al.
Advances in Therapy|March 8, 2014
Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sampleJason Yeaw, Crystal Watson, Kathleen M Fox, et al.
Pageof 6